Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) and HeartSciences (NASDAQ:HSCS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Valion Bio, Inc. Common Stock and HeartSciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Valion Bio, Inc. Common Stock | 1 | 0 | 0 | 0 | 1.00 |
| HeartSciences | 1 | 0 | 1 | 0 | 2.00 |
HeartSciences has a consensus target price of $8.00, indicating a potential upside of 298.01%. Given HeartSciences’ stronger consensus rating and higher possible upside, analysts plainly believe HeartSciences is more favorable than Valion Bio, Inc. Common Stock.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Valion Bio, Inc. Common Stock | N/A | -138.10% | -63.67% |
| HeartSciences | N/A | -333.50% | -140.18% |
Risk and Volatility
Valion Bio, Inc. Common Stock has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Comparatively, HeartSciences has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.
Insider & Institutional Ownership
4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 14.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Comparatively, 4.9% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Valion Bio, Inc. Common Stock and HeartSciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Valion Bio, Inc. Common Stock | $780,000.00 | 3.08 | -$8.88 million | ($6.68) | -0.11 |
| HeartSciences | N/A | N/A | -$8.77 million | ($4.94) | -0.41 |
HeartSciences has lower revenue, but higher earnings than Valion Bio, Inc. Common Stock. HeartSciences is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.
Summary
HeartSciences beats Valion Bio, Inc. Common Stock on 7 of the 12 factors compared between the two stocks.
About Valion Bio, Inc. Common Stock
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
About HeartSciences
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
